Prostate cancer: Enzalutamide PREVAILs

  title={Prostate cancer: Enzalutamide PREVAILs},
  author={Sarah Payton},
  journal={Nature Reviews Urology},
Enzalutamide PREVAILs Interim analysis of the PREVAIL trial, demonstrating the superiority of enzalutamide over placebo for patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), has now been published in The New England Journal of Medicine. The study data demonstrate that enzalutamide not only significantly improves… CONTINUE READING